Viral infections are common and are potentially life-threatening in patients with immune system disorders. Because immune cells (T-cells) contributes to the control of many viral infections, treatment with virus-specific T cells (VSTs) has been an effective way of combating severe viral disease in immunocompromised patients in prior studies. Common viral targets include cytomegalovirus, Epstein-Barr virus, and adenovirus, though recent published studies have successfully targeted additional infections, including HHV6, BK virus, and JC virus. Though most studies have used VSTs derived from bone marrow transplant donors, the use of pre-made VSTs from other healthy donors has shown efficacy in several studies. This approach could improve the accessibility of this therapy. In this review, we discuss the usage of VSTs for patients with primary immunodeficiency disorders in clinical trials, as well as future potential targets and methods to broaden the applicability of virus-directed T-cell immunotherapy for this vulnerable patient population.